P5178

Phenobarbital sodium salt

• Synonyme(s) : 5-Ethyl-5-phenyl-2,4,6-trioxohexahydropyrimidine sodium salt, 5-Ethyl-5-phenylbarbituric acid sodium salt, Luminal sodium salt, Sodium 5-ethyl-5-phenylbarbiturate
• Formule empirique (notation de Hill): C₁₂H₁₁N₂NaO₃
• Numéro CAS: 57-30-7
• Poids moléculaire : 254.22
• Numéro Beilstein : 3802044
• Numéro CE : 200-322-3
• Numéro MDL: MFCD00036211
• Code UNSPSC : 12352202
• ID de substance PubChem : 24898608
• Nomenclature NACRES : NA.77

Propriétés

• Forme: powder
• Contrôle du médicament: USDEA Schedule IV; Home Office Schedule 3; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)
• Solubilité: H₂O: 1 g/mL; ethanol: 100 mg/mL
• Auteur: Bayer
• Chaîne SMILES: [Na+].CCC1(C(=O)NC([O-])=NC1=O)c2ccccc2
• InChI: 1S/C12H12N2O3.Na/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16;/h3-7H,2H2,1H3,(H2,13,14,15,16,17);/q;+1/p-1
• Clé InChI: WRLGYAWRGXKSKG-UHFFFAOYSA-M

Description

Application

Phenobarbital sodium salt has been used:

• to anesthetize mice for inducing ischemia-reperfusion injury
• as a positive control for the activation of constitutive androstane receptor (CAR)
• in bioluminescent yeast bioreporters (BLYAS) assay

Actions biochimiques/physiologiques

Phenobarbital, a substituted barbituric acid is an antileptic drug and is not easily eliminated from circulation. It hyperpolarizes the synaptic neuronal membranes by favoring the activation of neuronal postsynaptic GABAA receptors by γ aminobutyric acid (GABA). Phenobarbital is also effective in treating neonatal seizures and status epilepticus.

Sedative; hypnotic; anticonvulsant; enhances GABAergic activity.

Caractéristiques et avantages

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the Dopamine and Norepinephrine Metabolism and GABAA Receptors pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informations sur la sécurité

• Pictogrammes: GHS06,GHS08
• Mention d'avertissement: Danger
• Mentions de danger: H301,H317,H351
• Conseils de prudence: P202 - P261 - P264 - P280 - P301 + P310 - P302 + P352
• Classification des risques: Acute Tox. 3 Oral - Carc. 2 - Skin Sens. 1
• Code de la classe de stockage: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable
• Équipement de protection individuelle: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges